Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.

Acorn Bioventures has led a series B round for the cancer-focused biopharmaceutical spinout of CU Boulder.

AbbVie has bought an exclusive option to acquire Mitokinin once the UCSF spinout completes IND-enabling studies for its Parkinson’s treatment.

Nationwide Ventures co-led a $15m series B round for the health data platform developer that included Aflac Corporate Ventures and Epsilon Health Investors.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

LabCorp Venture Fund, Bristol Myers Squibb and Takeda Ventures contributed to $7m in equity funding and a $6m convertible note for the cancer drug developer.

Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.

GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.

Laborie is set to exit the medical device manufacturer after another of its investors, Olympus, announced its intention to pay $260m for its remaining shares.

Osage University Partners has thrown its weight behind a series A2 round for Artizan, which is advancing work undertaken at Yale University.